Alector ALEC
Alector FY 2023: revenue $97.1M, down 27%; diluted EPS −$1.56
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-021183
- Document
- 10-K
- Exhibit 4.3
- Warrants or notes
- Exhibit 10.3
- Material contract
- Exhibit 10.4
- Material contract
- Exhibit 10.11
- Material contract
Key figures from this report
These are the numbers Alector reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$97.1M−27% from $133.6M in FY 202210-K income statement, on EDGAR
- Net income−$130.4MAgainst −$133.3M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$1.56Against −$1.62 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$74.6M−52% from $154.3M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$184.2MAgainst −$20.3M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
- Fate Therapeutics FATE public float $113M, Jun 30, 2025
- Caribou Biosciences CRBU public float $113M, Jun 30, 2025
- Protara Therapeutics PRTO public float $112M, Jun 30, 2025
- TuHURA Biosciences HURA public float $111M, Jun 30, 2025
